TP53 or Not TP53: That Is the Question

被引：0

作者：

Green, Steven D. ^{[1
]}

Zeidner, Joshua F. ^{[2
,3
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[3] Univ N Carolina, Dept Med, Div Hematol, 170 Manning Dr,Houpt Bldg,CB7305, Chapel Hill, NC 27599 USA

来源：

CLINICAL CANCER RESEARCH | 2022年 / 28卷 / 24期

关键词：

ACUTE MYELOID-LEUKEMIA; CLASSIFICATION; VALIDATION;

D O I：

10.1158/1078-0432.CCR-22-2664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.

引用

页码：5235 / 5237

页数：3

共 50 条

[1] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
Leroy, Bernard
Fournier, Jean Louis
Ishioka, Chikashi
Monti, Paola
Inga, Alberto
Fronza, Gilberto
Soussi, Thierry
[J]. NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
[2] TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy
Hu, Wanglai
Chen, Song
Thorne, Rick F.
Wu, Mian
[J]. AUTOPHAGY: BIOLOGY AND DISEASES: BASIC SCIENCE, 2019, 1206 : 127 - 149
[3] Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
Tesio, Melania
[J]. HEMASPHERE, 2023, 7 (02):
[4] TP53 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia
Lowe, Scott W.
[J]. BLOOD, 2019, 134
[5] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
Valk, Peter J. M.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
[6] Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
Saba, Karim H.
Difilippo, Valeria
Kovac, Michal
Cornmark, Louise
Magnusson, Linda
Nilsson, Jenny
van den Bos, Hilda
Spierings, Diana C. J.
Bidgoli, Mahtab
Jonson, Tord
Sumathi, Vaiyapuri P.
Brosjoe, Otte
Staaf, Johan
Foijer, Floris
Styring, Emelie
Nathrath, Michaela
Baumhoer, Daniel
Nord, Karolin H.
[J]. JOURNAL OF PATHOLOGY, 2024, 262 (02): : 147 - 160
[7] Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone
Ohnishi, T
Ohnishi, K
Wang, XJ
Takahashi, A
Okaichi, K
[J]. RADIATION RESEARCH, 1999, 151 (04) : 498 - 500
[8] Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
Trauernicht, Max
Rastogi, Chaitanya
Manzo, Stefano G.
Bussemaker, Harmen J.
van Steensel, Bas
[J]. NUCLEIC ACIDS RESEARCH, 2023, 51 (18) : 9690 - 9702
[9] Sarcomas in TP53 Germline Mutation Carriers A Review of the IARC TP53 Database
Ognjanovic, Simona
Olivier, Magali
Bergemann, Tracy L.
Hainaut, Pierre
[J]. CANCER, 2012, 118 (05) : 1387 - 1396
[10] TP53 and ovarian cancer
Schuijer, M
Berns, EMJJ
[J]. HUMAN MUTATION, 2003, 21 (03) : 285 - 291

← 1 2 3 4 5 →